B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients
Journal of Allergy and Clinical Immunology , Volume 133 - Issue 3
Background Adenosine deaminase (ADA) deficiency causes severe cellular and humoral immune defects and dysregulation because of metabolic toxicity. Alterations in B-cell development and function have been poorly studied. Enzyme replacement therapy (ERT) and hematopoietic stem cell (HSC) gene therapy (GT) are therapeutic options for patients lacking a suitable bone marrow (BM) transplant donor. Objective We sought to study alterations in B-cell development in ADA-deficient patients and investigate the ability of ERT and HSC-GT to restore normal B-cell differentiation and function. Methods Flow cytometry was used to characterize B-cell development in BM and the periphery. The percentage of gene-corrected B cells was measured by using quantitative PCR. B cells were assessed for their capacity to proliferate and release IgM after stimulation. Results Despite the severe peripheral B-cell lymphopenia, patients with ADA-deficient severe combined immunodeficiency showed a partial block in central BM development. Treatment with ERT or HSC-GT reverted most BM alterations, but ERT led to immature B-cell expansion. In the periphery transitional B cells accumulated under ERT, and the defect in maturation persisted long-term. HSC-GT led to a progressive improvement in B-cell numbers and development, along with increased levels of gene correction. The strongest selective advantage for ADA-transduced cells occurred at the transition from immature to naive cells. B-cell proliferative responses and differentiation to immunoglobulin secreting IgM after B-cell receptor and Toll-like receptor triggering were severely impaired after ERT and improved significantly after HSC-GT. Conclusions ADA-deficient patients show specific defects in B-cell development and functions that are differently corrected after ERT and HSC-GT.
|adenosine deaminase-deficient severe combined immunodeficiency, antibodies, B-cell development, Gene therapy|
|Journal of Allergy and Clinical Immunology|
Brigida, I, Sauer, A.V, Ferrua, F, Giannelli, S, Scaramuzza, S, Pistoia, V, … Aiuti, A. (2014). B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. Journal of Allergy and Clinical Immunology, 133(3). doi:10.1016/j.jaci.2013.12.1043